I am a healthcare professional


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.


For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

EAN 2022

Coming soon
01:30 PM
Duration 5mins Screen B3, Poster area in the Exhibition Hall
Disease Activity During Pregnancy and Postpartum in Women with Relapsing-Onset MS Receiving Ocrelizumab▼ in a Real-World Cohort
Yeh W, Van der Walt A, Kermode A, Kalincik T, Alroughani R, Lechner-Scott J, Boz C, Butler E, Buzzard K, Skibina O, Macdonell R, Willekens B, Prevost J, Terzi M, Liu C, Muros E, Pasquarelli N, Butzkueven H, Jokubaitis VG,on behalf of the MS Base Study Group
02:05 PM
Duration 5mins Hall B1
FIREFISH Parts 1 and 2: 36-month safety and efficacy of risdiplam▼ in Type 1 spinal ​muscular atrophy
Nicolas Deconinck, Giovanni Baranello, Odile Boespflug-Tanguy, John W Day, Andrea Klein, Riccardo Masson, Maria Mazurkiewicz-Beldzinska, Eugenio Mercuri, Kristy Rose, Laurent Servais, Dmitry Vlodavets, Hui Xiong, Edmar Zanoteli, Muna El-Khairi, Marianne Gerber, Ksenija Gorni, Heidemarie Kletzl, Angela Dodman, Eleni Gaki, Basil T Darras, on behalf of the FIREFISH Working Group
02:00 PM
Duration 5mins Hall B1
SUNFISH: 3-year efficacy and safety of risdiplam▼ in Types 2 and 3 spinal muscular atrophy
Nathalie Goemans, John W Day, Nicolas Deconinck, Janbernd Kirschner, Elena S Mazzone, Andres Nacimento, Maryam Oskoui, Kayoko Saito, Carole Vuillerot, Giovanni Baranello, Odile Boespflug-Tanguy, Anna Kostera-Pruszczyk, Laurent Servais, Jessica Braid, Marianne Gerber, Ksenija Gorni, Carmen Martin, Renata S Scalco, Wai Yin Yeung, Eugenio Mercuri, on behalf of the SUNFISH Working Group
06:00 PM
Duration 15mins Room Oslo
Efficacy and Safety of Ocrelizumab▼ in a Treatment-Naive, Early RMS Population: Data over 7 Years from the OPERA OLE Trials
Cerqueira J, Berthele A, Cree BAC, Filippi M, Pardo G, Pearson O, Traboulsee A, Ziemssen T, Vollmer T, Bernasconi C, Mandel C, Overell J, Havrdova EK